

COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT



Molecular Diagnostics at the Point of Care

By Application, Technology, Place, Product and by Country. With **COVID-19 PoC Breakout** and Executive Guides and Customization 2021 - 2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- 1 Market Guides25
 - 1.1 Molecular Diagnostics at the Point of Care - Strategic Situation Analysis and Impact of COVID-19. 26
 - 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 28
 - 1.3 Guide for Management Consultants and Investment Advisors 29
- 2 Introduction and Market Definition30
 - 2.1 What are Molecular Diagnostics at the Point of Care? 31
 - 2.2 The Diagnostics Revolution..... 33
 - 2.3 Market Definition 35
 - 2.3.1 Revenues..... 35
 - 2.4 Methodology..... 37
 - 2.4.1 Authors 37
 - 2.4.2 Sources 37
 - 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic 38
 - 2.5.1 Global Healthcare Spending 38
 - 2.5.2 Spending on Diagnostics 40
 - 2.5.3 Important Role of Insurance for Diagnostics 41
- 3 The Infectious Diseases – Market Analysis by Disease42
 - 3.1 HIV - Human Immunodeficiency Virus (AIDS) 43
 - 3.1.1 Virology 43

- 3.1.1.1 Classification 43
- 3.1.1.2 Structure and genome..... 44
- 3.1.1.3 Tropism..... 47
- 3.1.1.4 Replication cycle..... 49
- 3.1.1.5 Genetic variability 55
- 3.1.2 Diagnosis 56
- 3.1.3 Testing..... 58
 - 3.1.3.1 Antibody tests 58
 - 3.1.3.2 Point of Care Tests (POCT) 61
 - 3.1.3.3 Antigen Tests 64
 - 3.1.3.4 Nucleic acid-based tests (NAT) 64
 - 3.1.3.5 Other tests used in HIV treatment..... 65
- 3.1.4 Market Opportunity Analysis 66
- 3.2 HBV – Hepatitis B..... 71
 - 3.2.1 Virology 72
 - 3.2.1.1 Genome 73
 - 3.2.1.2 Pathogenesis..... 74
 - 3.2.1.3 Hepatitis B virus replication 74
 - 3.2.1.4 Serotypes and genotypes..... 75
 - 3.2.2 Mechanisms..... 75
 - 3.2.3 Diagnosis 76
 - 3.2.4 Market Opportunity Analysis 77
- 3.3 HCV – Hepatitis C..... 79
 - 3.3.1 Taxonomy..... 80

- 3.3.2 Structure 81
 - 3.3.2.1 Genome 81
- 3.3.3 Molecular biology 82
- 3.3.4 Replication..... 84
- 3.3.5 Genotypes 85
 - 3.3.5.1 Clinical importance..... 86
- 3.3.6 Market Opportunity Analysis 86
- 3.4 HPV - Human papillomavirus..... 88
 - 3.4.1 Virology 90
 - 3.4.1.1 E6/E7 proteins..... 90
 - 3.4.1.2 Role in cancer..... 90
 - 3.4.1.3 E2 research..... 91
 - 3.4.1.4 Latency period 93
 - 3.4.1.5 Clearance 93
 - 3.4.2 Diagnosis 93
 - 3.4.2.1 Cervical testing 93
 - 3.4.2.2 Oral testing 95
 - 3.4.2.3 Testing men 95
 - 3.4.2.4 Other testing 97
 - 3.4.3 Market Opportunity Analysis 97
- 3.5 Influenza..... 103
 - 3.5.1 Virology 105
 - 3.5.1.1 Types of virus 105
 - 3.5.1.2 Influenzavirus A 105

- 3.5.1.3 Influenzavirus B 106
- 3.5.1.4 Influenzavirus C 106
- 3.5.1.5 Structure, properties, and subtype nomenclature 106
- 3.5.1.6 Replication 108
- 3.5.2 Testing..... 110
 - 3.5.2.1 Advantages/Disadvantages of Molecular Assays..... 112
- 3.5.3 Market Opportunity Analysis 113
- 3.6 CTGC - Chlamydia/Gonorhea 123
 - 3.6.1 Gonorrhoea 123
 - 3.6.1.1 Diagnosis 124
 - 3.6.1.2 Screening 124
 - 3.6.2 Chlamydia 124
 - 3.6.2.1 Diagnosis 125
 - 3.6.2.2 Screening 126
 - 3.6.3 Testing..... 127
 - 3.6.3.1 Nucleic acid amplification tests (NAATs)..... 127
 - 3.6.3.2 Performance of NAAT Tests..... 136
 - 3.6.4 Market Opportunity Analysis 137
- 3.7 Tuberculosis..... 139
 - 3.7.1 Mycobacteria..... 140
 - 3.7.2 Diagnosis 142
 - 3.7.2.1 Active tuberculosis 142
 - 3.7.2.2 Latent tuberculosis..... 142
 - 3.7.3 Epidemiology 143

- 3.7.4 Molecular Diagnostic Tests 145
- 3.7.5 Market Opportunity Analysis 146
- 3.8 MRSA - Methicillin-resistant Staphylococcus aureus 148
 - 3.8.1 Diagnosis 148
 - 3.8.2 FDA Approved Molecular Tests 149
 - 3.8.3 Market Opportunity Analysis 150
- 3.9 VRE - Vancomycin-resistant Enterococcus..... 152
 - 3.9.1 FDA Approved MDx Tests for VRE..... 153
 - 3.9.2 Market Opportunity Analysis 154
- 3.10 Blood Screening 155
 - 3.10.1 Collection and Testing 155
 - 3.10.2 FDA Approved Multiplex Assays..... 156
 - 3.10.3 Market Opportunity Analysis 158
- 3.11 COVID-19 159
 - 3.11.1 Signs and symptoms..... 160
 - 3.11.2 Transmission..... 162
 - 3.11.3 Diagnosis 163
 - 3.11.4 Prevention 165
 - 3.11.5 Management 166
 - 3.11.6 Prognosis 167
- 3.12 Pandemic Diagnostics 168
 - 3.12.1 Risk Management – Spark and Spread 168
 - 3.12.2 Dx Technology – Nucleic Acid Based..... 170
 - 3.12.3 Dx Technology - Immunoassay & Serology 171

- 3.12.4 Time to Market and Preparedness Issues 172
- 3.12.5 Unrecognized Role of Multiplex in Pandemic Mangement..... 172
- 4 Industry Overview.....174
- 4.1 Players in a Dynamic Market..... 175
 - 4.1.1 Academic Research Lab 176
 - 4.1.2 Diagnostic Test Developer..... 176
 - 4.1.3 Instrumentation Supplier 176
 - 4.1.4 Distributor and Reagent Supplier 177
 - 4.1.5 Independent Testing Lab..... 177
 - 4.1.6 Public National/regional lab 178
 - 4.1.7 Hospital lab 178
 - 4.1.8 Physician Office Labs and Clinics 179
 - 4.1.9 Audit Body 179
 - 4.1.10 Certification Body..... 179
- 4.2 The Clinical Laboratory Market Segments 181
 - 4.2.1 Traditional Market Segmentation..... 181
 - 4.2.2 Laboratory Focus and Segmentation..... 183
- 4.3 Industry Structure..... 185
 - 4.3.1 Hospital Testing Share 185
 - 4.3.2 Economies of Scale..... 185
 - 4.3.2.1 Hospital vs. Central Lab..... 186
 - 4.3.3 Physician Office Lab's..... 187
 - 4.3.4 Physician's and POCT 187
- 5 Profiles of Key MDx Companies 189

5.1 Abacus Diagnostica 190

5.2 Abbott Diagnostics 191

5.3 Accelerate Diagnostics 193

5.4 Ador Diagnostics 194

5.5 Akonni Biosystems 195

5.6 Alveo Technologies..... 196

5.7 Applied BioCode 197

5.8 Aus Diagnostics 199

5.9 Beckman Coulter Diagnostics..... 200

5.10 Becton, Dickinson and Company 201

5.11 Binx Health 203

5.12 Biocartis..... 204

5.13 bioMérieux Diagnostics..... 205

5.14 Bio-Rad Laboratories, Inc..... 208

5.15 Bosch Healthcare Solutions GmbH 210

5.16 Cepheid (now Danaher) 211

5.17 Chembio 212

5.18 Co Diagnostics 213

5.19 Credo Diagnostics Biomedical 214

5.20 Cue Health..... 215

5.21 Curetis N.V. / Curetis GmbH 216

5.22 Diagenode Diagnostics 217

5.23 Diascopic 218

5.24 Diasorin S.p.A. 219

5.25 Eiken Chemical 220

5.26 Enzo Life Sciences, Inc. 221

5.27 Eurofins Scientific 223

5.28 Fluxergy 225

5.29 Fulgent Genetics 226

5.30 Fusion Genomics. 227

5.31 Genedrive..... 229

5.32 Genetic Signatures..... 230

5.33 GenMark Dx..... 231

5.34 Grifols..... 233

5.35 HiberGene Diagnostics..... 234

5.36 Hologic 235

5.37 Illumina 237

5.38 Immunexpress..... 238

5.39 Inflammatix 239

5.40 Invetech..... 240

5.41 Janssen Diagnostics 241

5.42 Karius 242

5.43 Lexogene 243

5.44 LightDeck Diagnostics 244

5.45 Luminex Corp 245

5.46 Lumos Diagnostics..... 247

5.47 Mammoth Biosciences 248

5.48 Maxim Biomedical 249

5.49 Meridian Bioscience..... 250

5.50 Mesa Biotech..... 252

5.51 Millipore Sigma 253

5.52 Mindray 254

5.53 Mobidiag 255

5.54 Nanomix..... 256

5.55 Operon..... 257

5.56 Oxford Nanopore Technologies 258

5.57 Panagene..... 259

5.58 Perkin Elmer..... 260

5.59 Primerdesign 262

5.60 Prominex 263

5.61 Qiagen Gmbh 264

5.62 Quantumdx 266

5.63 Quidel..... 267

5.64 Roche Molecular Diagnostics 269

5.65 Saw Diagnostics 271

5.66 Seegene..... 272

5.67 Siemens Healthineers 273

5.68 Sona Nanotech 276

5.69 SpeeDx..... 277

5.70 T2 Biosystems..... 278

5.71 Thermo Fisher Scientific Inc..... 279

5.72 Veramarx 281

5.73 Veredus Laboratories..... 282

5.74 Vir..... 283

5.75 XCR Diagnostics 284

6 Market Trends285

6.1 Factors Driving Growth 286

6.1.1 New Genotypes Creating New Markets 287

6.1.2 Aging Population a Boon for All Diagnostics 287

6.1.3 Developing World Driving ID Dx Growth..... 288

6.1.4 Point of Care – Why Centralization is Losing Steam 288

6.1.5 Self Testing..... 289

6.1.6 The Need for Speed 289

6.1.7 The COVID Pandemic..... 289

6.2 Factors Limiting Growth 290

6.2.1 Lower Costs..... 290

6.2.2 Infectious Disease is Declining 292

6.2.3 Wellness Hurts..... 292

6.2.4 Economic Growth improves Living Standards 292

6.3 Instrumentation and Automation 293

6.3.1 Instruments Key to Market Share 293

6.3.2 The Shrinking Machine 293

6.3.3 Multiplex, Point of Care and The Speed Factor..... 293

6.4 Diagnostic Technology Development 295

6.4.1 The Sepsis Testing Market – A New Direction? 296

6.4.2 POCT/Self Testing as a Disruptive Force 296

- 6.4.3 The Genetics Play – One Test for All Known Infections..... 297
- 6.4.4 Antibiotic Resistance Genes – Simplifying Diagnostics..... 297
- 7 Molecular Dx – Infectious Disease Recent Developments298
 - 7.1 Recent Developments – Importance and How to Use This Section 299
 - 7.1.1 Importance of These Developments 299
 - 7.1.2 How to Use This Section..... 299
 - 7.2 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform 299
 - 7.3 Talis Biomedical Discusses Point-of-Care..... 303
 - 7.4 Roche to Acquire GenMark Diagnostics for \$1.8B 307
 - 7.5 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization..... 308
 - 7.6 Hologic to Acquire Mobidiag 316
 - 7.7 Lucira Health Focuses on User Friendly Approach to Home Testing 317
 - 7.8 Infectious Disease Dx Firm Talis Biomedical Raises \$254M in IPO..... 323
 - 7.9 Fluidigm Plans 'Durable' Diagnostics, Clinical Business..... 323
 - 7.10 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to \$550M 327
 - 7.11 Mammoth Biosciences Developing Pathogen Detection Tech 328
 - 7.12 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests 331
 - 7.13 Scanogen Developing 90 Minute Infection Test..... 336
 - 7.14 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection 339
 - 7.15 FDA Provides Self Testing SARS-CoV-2 EAU Guidance 342
 - 7.16 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic 344
 - 7.17 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test 345
 - 7.18 Qiagen Respiratory Panel with Coronavirus Receives CE Mark..... 346
 - 7.19 Lumos Diagnostics Closes \$15M Series A Funding 347

- 7.20 Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay 348
- 7.21 New Genomic Tests Diagnose Deadly Infections Faster 349
- 7.22 Biotia Raises \$2.4M Seed Round 354
- 7.23 STDs resurge in US 356
- 7.24 Ares Genetics signs R&D agreement with leading global IVD corporation..... 357
- 7.25 Cell-Free DNA Used for Infectious Disease Testing 358
- 7.26 One BioMed Raises \$5M 359
- 8 The Global Market for Molecular Diagnostics at the Point of Care361
 - 8.1 Global Market Overview by Country 362
 - 8.1.1 Table – Global Market by Country..... 362
 - 8.1.2 Chart - Global Market by Country 363
 - 8.2 Global Market by Application - Overview..... 364
 - 8.2.1 Table – Global Market by Application 364
 - 8.2.2 Chart – Global Market by Application – Base/Final Year Comparison 365
 - 8.2.3 Chart – Global Market by Application – Base Year 366
 - 8.2.4 Chart – Global Market by Application – End Year 367
 - 8.2.5 Chart – Global Market by Application – Share by Year..... 368
 - 8.2.6 Chart – Global Market by Application – Segments Growth..... 369
 - 8.3 Global Market by Technology - Overview..... 370
 - 8.3.1 Table – Global Market by Technology 370
 - 8.3.2 Chart – Global Market by Technology – Base/Final Year Comparison 371
 - 8.3.3 Chart – Global Market by Technology – Base Year 372
 - 8.3.4 Chart – Global Market by Technology – End Year 373
 - 8.3.5 Chart – Global Market by Technology – Share by Year..... 374

- 8.3.6 Chart – Global Market by Technology – Segments Growth..... 375
- 8.4 Global Market by Place - Overview 376
 - 8.4.1 Table – Global Market by Place..... 376
 - 8.4.2 Chart – Global Market by Place – Base/Final Year Comparison 377
 - 8.4.3 Chart – Global Market by Place – Base Year..... 378
 - 8.4.4 Chart – Global Market by Place – End Year 379
 - 8.4.5 Chart – Global Market by Place – Share by Year..... 380
 - 8.4.6 Chart – Global Market by Place – Segments Growth 381
- 8.5 Global Market by Product - Overview 382
 - 8.5.1 Table – Global Market by Product..... 382
 - 8.5.2 Chart – Global Market by Product – Base/Final Year Comparison..... 383
 - 8.5.3 Chart – Global Market by Product – Base Year..... 384
 - 8.5.4 Chart – Global Market by Product – End Year 385
 - 8.5.5 Chart – Global Market by Product – Share by Year..... 386
 - 8.5.6 Chart – Global Market by Product – Segments Growth 387
- 9 Global MDx at the Point of Care Markets – By Application388
 - 9.1 Covid - 19..... 389
 - 9.1.1 Table Covid - 19 – by Country 389
 - 9.1.2 Chart - Covid - 19 Growth 390
 - 9.2 Respiratory Infectious Disease..... 391
 - 9.2.1 Table Respiratory Infectious Disease – by Country 391
 - 9.2.2 Chart - Respiratory Infectious Disease Growth 392
 - 9.3 Gastrointestinal Infectious Disease 393
 - 9.3.1 Table Gastrointestinal Infectious Disease – by Country..... 393

9.3.2 Chart - Gastrointestinal Infectious Disease Growth 394

9.4 Sexually Transmitted Disease..... 395

9.4.1 Table Sexually Transmitted Disease – by Country 395

9.4.2 Chart - Sexually Transmitted Disease Growth 396

9.5 Other Application 396

9.5.1 Table Other Application – by Country..... 396

9.5.2 Chart - Other Application Growth 397

10 Global MDx Markets at the Point of Care – by Technology399

10.1 PCR..... 400

10.1.1 Table PCR – by Country 400

10.1.2 Chart - PCR Growth..... 401

10.2 NGS/Probe 402

10.2.1 Table NGS/Probe – by Country 402

10.2.2 Chart - NGS/Probe Growth..... 403

10.3 Other Technology 404

10.3.1 Table Other Technology – by Country..... 404

10.3.2 Chart - Other Technology Growth 405

11 Global MDx at the Point of Care Markets – by Place406

11.1 Hospital Point of Care 407

11.1.1 Table Hospital Point of Care – by Country 407

11.1.2 Chart - Hospital Point of Care Growth..... 408

11.2 Clinic or Physician Office Lab..... 409

11.2.1 Table Clinic or Physician Office Lab – by Country 409

11.2.2 Chart - Clinic or Physician Office Lab Growth 410

- 11.3 Seniors Facility 411
 - 11.3.1 Table Seniors Facility – by Country 411
 - 11.3.2 Chart – Seniors Facility Growth 412
- 11.4 Other Place 413
 - 11.4.1 Table Other Place– by Country 413
 - 11.4.2 Chart – Other Place Growth..... 414
- 12 Global MDx at the Point of Care Markets – by Product415
 - 12.1 Instrument 416
 - 12.1.1 Table Instrument – by Country 416
 - 12.1.2 Chart - Instrument Growth 417
 - 12.2 Cartridge..... 418
 - 12.2.1 Table Cartridge – by Country 418
 - 12.2.2 Chart - Cartridge Growth 419
 - 12.3 Other Product..... 420
 - 12.3.1 Table Other Product – by Country 420
 - 12.3.2 Chart – Other Product Growth..... 421
- 13 Appendices422
 - 13.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule 423

Table of Tables

Table 1 Classification of HIV Species.....	44
Table 2 HIV Tests - CMS Codes & Prices	67
Table 3 Current HIV Molecular Tests and Instruments Used.....	68
Table 4 HBV Tests - CMS Codes & Prices	79
Table 5 HCV Tests - CMS Codes & Prices	87
Table 6 HPV Clearance Rates	93
Table 7 HPV Tests - CMS Codes & Prices.....	98
Table 8 HPV Tests, Technology, Types	99
Table 9 Types of Influenza Tests	111
Table 10 Influenza Tests - CMS Codes & Prices.....	114
Table 11 FDA Cleared Molecular Assays for Influenza	115
Table 12 FDA Cleared NAAT CTGC Tests	129
Table 13 CTGC NAAT Target Sequences and Possible False Reactions	133
Table 14 CTGC Tests - CMS Codes & Prices.....	138
Table 15 FDA Approved MDx Tests for Tuberculosis	145
Table 16 Tuberculosis Tests - CMS Codes & Prices.....	146
Table 17 FDA Approved Tests for MRSA	149
Table 18 MRSA Tests - CMS Codes & Prices	151
Table 19 FDA Approved Tests for VRE	153
Table 20 VRE Tests - CMS Codes & Prices	154

Table 21 FDA Approved Multiplex Assays 156

Table 22 Characteristics of Coronavirus Pandemic Infections 159

Table 23 COVID-19 Symptoms..... 161

Table 24 Market Players by Type 175

Table 25 Clinical Laboratory Departments and Segments 182

Table 26 Laboratory Management Focus – Different Approaches 183

Table 27 Key Segmentation Variables Going Forward..... 184

Table 28 Five Factors Driving Growth 286

Table 29 Four Factors Limiting Growth 290

Table 30 Key Diagnostic Laboratory Technology Trends 295

Table 31 - Global Market by Region 362

Table 32 Global Market by Application..... 364

Table 33 Global Market by Technology 370

Table 34 Global Market by Place..... 376

Table 35 Global Market by Product..... 382

Table 36 Covid - 19 by Country 389

Table 37 Respiratory Infectious Disease by Country 391

Table 38 Gastrointestinal Infectious Disease by Country..... 393

Table 39 Sexually Transmitted Disease by Country 395

Table 40 Other Application by Country..... 396

Table 41 PCR by Country 400

Table 42 NGS/Probe by Country 402

Table 43 Other Technology by Country..... 404

Table 44 Hospital Point of Care by Country 407

Table 45 Clinic or Physician Office Lab by Country	409
Table 46 Seniors Facility by Country	411
Table 47 Other Place by Country	413
Table 48 Instrument by Country	416
Table 49 Cartridge by Country	418
Table 50 Other Product by Country	420
Table 51 2021 Clinical Lab Fee Schedule	423

Table of Figures

Figure 1 Map - Global Healthcare Spending Per Capita.....	39
Figure 2 The Lab Test Pie - Wholesale vs. Retail.....	40
Figure 3 HIV Virion	45
Figure 4 Diagram of the HIV Replication Cycle	49
Figure 5 The Structure of the HBV Virus.....	73
Figure 6 Hepatitis B Replication	74
Figure 7 Structure of the HCV Virus.....	81
Figure 8 HCV Replication Cycle	84
Figure 9 Structure of the Influenza Virion	107
Figure 10 Influenza Replication.....	108
Figure 11 Scanning Electronmicrograph of Tuberculosis.....	141
Figure 12 Percentage of World Population Over 65.....	288
Figure 13 Chart Infectious Disease Decline	291
Figure 14 Global Market Shares Chart	363
Figure 15 Global Market by Application - Base vs. Final	365
Figure 16 Global Market by Application Base Year.....	366
Figure 17 Global Market by Application End Year	367
Figure 18 Application Share by Year.....	368
Figure 19 Application Segments Growth	369
Figure 20 Global Market by Technology - Base vs. Final	371
Figure 21 Global Market by Technology Base Year.....	372

Figure 22 Global Market by Technology End Year 373

Figure 23 Technology Share by Year..... 374

Figure 24 Technology Segments Growth 375

Figure 25 Global Market by Place - Base vs. Final..... 377

Figure 26 Global Market by Place Base Year 378

Figure 27 Global Market by Place End Year 379

Figure 28 Place Share by Year..... 380

Figure 29 Place Segments Growth 381

Figure 30 Global Market by Product - Base vs. Final..... 383

Figure 31 Global Market by Product Base Year 384

Figure 32 Global Market by Product End Year 385

Figure 33 Product Share by Year 386

Figure 34 Product Segments Growth 387

Figure 35 Covid - 19 Growth 390

Figure 36 Other Infectious Disease Diagnostics Growth 392

Figure 37 Gastrointestinal Infectious Disease Growth 394

Figure 38 Sexually Transmitted Disease Growth 396

Figure 39 Other Application Growth 398

Figure 40 PCR Growth 401

Figure 41 NGS/Probe Growth 403

Figure 42 Other Technology Growth 405

Figure 43 Hospital Point of Care Growth..... 408

Figure 44 Clinic or Physician Office Lab Growth 410

Figure 45 Seniors Facility Growth 412

Figure 46 Other Place Growth 414

Figure 47 Instrument Growth 417

Figure 48 Cartridge Growth 419

Figure 49 Other Product Growth 421